Diagnostic and prognostic contribution of DPD scintigraphy in transthyretin V30M cardiac amyloidosis

References

• González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36:2585–2594. doi:10.1093/eurheartj/ehv338.
   PubMed Web of Science ®Google Scholar
• Hahn VS, Yanek LR, Vaishnav J, et al. Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis. JACC Heart Fail. 2020;8:712–724. doi:10.1016/j.jchf.2020.04.007.
   PubMed Web of Science ®Google Scholar
• Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:22–31. doi:10.1056/NEJMoa1716793.
   PubMed Web of Science ®Google Scholar
• Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11–21. doi:10.1056/NEJMoa1716153.
   PubMed Web of Science ®Google Scholar
• Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007–1016. doi:10.1056/NEJMoa1805689.
   PubMed Web of Science ®Google Scholar
• Saraiva MJ, Birken S, Costa PP, et al. Amyloid fibril protein in familial amyloidotic polyneuropathy, portuguese type. Definition of molecular abnormality in transthyretin (prealbumin). J Clin Invest. 1984;74:104–119. doi:10.1172/JCI111390.
   PubMed Web of Science ®Google Scholar
• Andrade C. A peculiar form of peripheral neuropathy. Acta Psychiatr Neurol Scand. 1951;26:251–257. doi:10.1111/j.1600-0447.1951.tb09673.x.
   PubMedGoogle Scholar
• Coutinho P, Martins da Silva P, Lopes Lima J. Forty years of experience with type I amyloid neuropathy: review of 438 cases. In: Glenner G, Costa P, de Freitas F, editor. Amyloid and amyloidosis. Amsterdam: Excerpta Medica; 1980:88–98.
   Google Scholar
• Coutinho MCA, Cortez-Dias N, Cantinho G, et al. Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy. Circ Cardiovasc Imaging. 2013;6:627–636. doi:10.1161/CIRCIMAGING.112.000367.
   PubMed Web of Science ®Google Scholar
• Suhr OB, Lindqvist P, Olofsson B-O, et al. Myocardial hypertrophy and function are related to age at onset in familial amyloidotic polyneuropathy. Amyloid. 2006;13:154–159. doi:10.1080/13506120600876849.
   PubMed Web of Science ®Google Scholar
• Sobue G, Koike H, Misu K, et al. Clinicopathologic and genetic features of early- and late-onset FAP type I (FAP ATTR Val30Met) in Japan. Amyloid. 2003;10(Suppl 1):32–38. doi:10.1080/13506129.2003.12088566.
   PubMed Web of Science ®Google Scholar
• Koike H, Misu K, Ikeda S, et al. Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch Neurol. 2002;59(11):1771–1776. doi:10.1001/archneur.59.11.1771.
   PubMedGoogle Scholar
• Misu KI, Hattori N, Nagamatsu M, et al. Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features. Brain. 1999;122(Pt 10):1951–1962. doi:10.1093/brain/122.10.1951.
   PubMedGoogle Scholar
• Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46(6):1076–1084. doi:10.1016/j.jacc.2005.05.073.
   PubMed Web of Science ®Google Scholar
• Musumeci MB, Cappelli F, Russo D, et al. Low sensitivity of bone scintigraphy in detecting Phe64Leu mutation-related transthyretin cardiac amyloidosis. JACC Cardiovasc Imaging. 2020;13(6):1314–1321. doi:10.1016/j.jcmg.2019.10.015.
   PubMed Web of Science ®Google Scholar
• Azevedo Coutinho MC, Cortez-Dias N, Cantinho G, et al. The sensitivity of DPD scintigraphy to detect transthyretin cardiac amyloidosis in V30M mutation depends on the phenotypic expression of the disease. Amyloid. 2020;27(3):174–183. doi:10.1080/13506129.2020.1744553.
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Quarta CC, Guidalotti PL, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging. 2011;4(6):659–670. doi:10.1016/j.jcmg.2011.03.016.
   PubMed Web of Science ®Google Scholar
• Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1–39.e14. doi:10.1016/j.echo.2014.10.003.
   PubMed Web of Science ®Google Scholar
• Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2016;17(12):1321–1360. doi:10.1093/ehjci/jew082.
   PubMed Web of Science ®Google Scholar
• Poterucha TJ, Elias P, Ruberg FL, et al. False positive 99mTc-Pyrophosphate scanning leading to inappropriate tafamidis prescriptions. JACC Cardiovasc Imaging. 2021;14(10):2042–2044. doi:10.1016/j.jcmg.2021.04.006.
   PubMed Web of Science ®Google Scholar
• Bokhari S, Castaño A, Pozniakoff T, et al. (99m)tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6(2):195–201. doi:10.1161/CIRCIMAGING.112.000132.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis, tours, France, 18-22 april 2004. Am J Hematol. 2005;79(4):319–328. doi:10.1002/ajh.20381.
   PubMed Web of Science ®Google Scholar
• Carrió I, Cowie MR, Yamazaki J, et al. Cardiac sympathetic imaging with mIBG in heart failure. JACC Cardiovasc Imaging. 2010;3(1):92–100. doi:10.1016/j.jcmg.2009.07.014.
   PubMed Web of Science ®Google Scholar
• Jacobson AF, Senior R, Cerqueira MD, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView myocardial imaging for risk evaluation in heart failure) study. J Am Coll Cardiol. 2010;55(20):2212–2221. doi:10.1016/j.jacc.2010.01.014.
   PubMed Web of Science ®Google Scholar
• Azevedo Coutinho MdC, Cortez-Dias N, Cantinho G, et al. Progression of myocardial sympathetic denervation assessed by (123)I-MIBG imaging in familial amyloid polyneuropathy and the effect of liver transplantation. Rev Port Cardiol. 2017;36(5):333–340. doi:10.1016/j.repc.2016.08.010.
   PubMedGoogle Scholar
• Pilebro B, Suhr OB, Näslund U, et al. (99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis. Ups J Med Sci. 2016;121(1):17–24. doi:10.3109/03009734.2015.1122687.
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–2412. doi:10.1161/CIRCULATIONAHA.116.021612.
   PubMed Web of Science ®Google Scholar
• Ihse E, Ybo A, Suhr O, et al. Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol. 2008;216(2):253–261. doi:10.1002/path.2411.
   PubMed Web of Science ®Google Scholar
• Bergström J, Gustavsson A, Hellman U, et al. Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology. J Pathol. 2005;206(2):224–232. doi:10.1002/path.1759.
   PubMed Web of Science ®Google Scholar
• Kristen AV, Scherer K, Buss S, et al. Noninvasive risk stratification of patients with transthyretin amyloidosis. JACC Cardiovasc Imaging. 2014;7(5):502–510. doi:10.1016/j.jcmg.2014.03.002.
   PubMed Web of Science ®Google Scholar
• Castano A, Haq M, Narotsky DL, et al. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients With ATTR cardiac amyloidosis. JAMA Cardiol. 2016;1(8):880–889. doi:10.1001/jamacardio.2016.2839.
   PubMed Web of Science ®Google Scholar
• Stangou AJ, Hawkins PN, Heaton ND, et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. Transplantation. 1998;66(2):229–233. doi:10.1097/00007890-199807270-00016.
   PubMed Web of Science ®Google Scholar
• Dubrey SW, Davidoff R, Skinner M, et al. Progression of ventricular wall thickening after liver transplantation for familial amyloidosis. Transplantation. 1997;64(1):74–80. doi:10.1097/00007890-199707150-00014.
   PubMed Web of Science ®Google Scholar
• Okamoto S, Hörnsten R, Obayashi K, et al. Continuous development of arrhythmia is observed in swedish transplant patients with familial amyloidotic polyneuropathy (amyloidogenic transthyretin Val30Met variant). Liver Transpl. 2011;17(2):122–128. doi:10.1002/lt.22184.
   PubMed Web of Science ®Google Scholar
• Hörnsten R, Wiklund U, Olofsson B-O, et al. Liver transplantation does not prevent the development of life-threatening arrhythmia in familial amyloidotic polyneuropathy, portuguese-type (ATTR Val30Met) patients. Transplantation. 2004;78(1):112–116. doi:10.1097/01.tp.0000133517.20972.27.
   PubMed Web of Science ®Google Scholar
• Delahaye N, Rouzet F, Sarda L, et al. Impact of liver transplantation on cardiac autonomic denervation in familial amyloid polyneuropathy. Medicine (Baltimore). 2006;85(4):229–238. doi:10.1097/01.md.0000232559.22098.c3.
   PubMed Web of Science ®Google Scholar
• Okamoto S, Yamashita T, Ando Y, et al. Evaluation of myocardial changes in familial amyloid polyneuropathy after liver transplantation. Intern Med. 2008;47(24):2133–2137. doi:10.2169/internalmedicine.47.1399.
   PubMed Web of Science ®Google Scholar